Phase
Condition
Covid-19
Treatment
Panbio™ COVID-19/Flu A&B Panel
Clinical Study ID
Ages > 2 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participant is at least two (2) years of age, and
Participant is suspected of acute viral respiratory infection by a healthcareprofessional, and
Participant is within seven (7) days of symptom onset, and
Participant is experiencing two or more of the following symptoms
Fever of >100.0°F/ 37.8°C
Cough
Fatigue
New loss of taste or smell
Congestion or runny nose
Shortness of breath or difficulty breathing
Sore throat
Muscle or body aches
Headache
Nausea or vomiting
Diarrhea
Exclusion
Exclusion Criteria:
Participant is currently enrolled in a study to evaluate an investigational drug orexperimental treatment
Participants with an active nosebleed
Participant has undergone a nasal wash or nasal aspirate procedure on day ofenrolment
Participant has received a nasal spray or mist Influenza vaccine (i.e. FluMist)within the last 30 days
Participant has tested positive for COVID-19 within the last 45 days (excluding testresults received after current onset of symptoms)
Participant has received antiviral medications for Influenza (Amantadine,Rimantadine, Ribavirin, Oseltamivir, Zanamivir) in the previous 45 days
Participant has received medication or treatment for COVID-19 infection in the last 45 days (including antivirals, convalescent plasma therapy, monoclonal antibodytreatment (mAb), Remdesivir, long-acting antibody (LAAB) treatment (Evusheld)
Study Design
Study Description
Connect with a study center
Cahaba Research Inc
Pelham, Alabama 35124
United StatesSite Not Available
Maimonides Medical Center
Brooklyn, New York 11219
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.